Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge.

Bukreyev A, Marzi A, Feldmann F, Zhang L, Yang L, Ward JM, Dorward DW, Pickles RJ, Murphy BR, Feldmann H, Collins PL.

Virology. 2009 Jan 20;383(2):348-61. doi: 10.1016/j.virol.2008.09.030.

2.

A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.

Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, Murphy BR, Collins PL, Sanchez A.

J Virol. 2006 Mar;80(5):2267-79.

3.

Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.

Bukreyev AA, Dinapoli JM, Yang L, Murphy BR, Collins PL.

Virology. 2010 Apr 10;399(2):290-8. doi: 10.1016/j.virol.2010.01.015.

4.

A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals.

Yang L, Sanchez A, Ward JM, Murphy BR, Collins PL, Bukreyev A.

Virology. 2008 Aug 1;377(2):255-64. doi: 10.1016/j.virol.2008.04.029.

6.
7.

Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.

DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A.

Vaccine. 2010 Dec 10;29(1):17-25. doi: 10.1016/j.vaccine.2010.10.024.

9.

Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.

Meyer M, Garron T, Lubaki NM, Mire CE, Fenton KA, Klages C, Olinger GG, Geisbert TW, Collins PL, Bukreyev A.

J Clin Invest. 2015 Aug 3;125(8):3241-55. doi: 10.1172/JCI81532.

11.

Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection.

Marzi A, Murphy AA, Feldmann F, Parkins CJ, Haddock E, Hanley PW, Emery MJ, Engelmann F, Messaoudi I, Feldmann H, Jarvis MA.

Sci Rep. 2016 Feb 15;6:21674. doi: 10.1038/srep21674.

12.

Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection.

Reynard O, Mokhonov V, Mokhonova E, Leung J, Page A, Mateo M, Pyankova O, Georges-Courbot MC, Raoul H, Khromykh AA, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S1060-5. doi: 10.1093/infdis/jir347.

13.

Successful topical respiratory tract immunization of primates against Ebola virus.

Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, Murphy BR, Collins PL, Sanchez A.

J Virol. 2007 Jun;81(12):6379-88.

14.

Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents.

Wong G, Audet J, Fernando L, Fausther-Bovendo H, Alimonti JB, Kobinger GP, Qiu X.

Vaccine. 2014 Sep 29;32(43):5722-9. doi: 10.1016/j.vaccine.2014.08.028.

PMID:
25173474
15.

A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine.

Kobayashi H, Iwatsuki-Horimoto K, Kiso M, Uraki R, Ichiko Y, Takimoto T, Kawaoka Y.

Vaccine. 2013 Dec 16;31(52):6239-46. doi: 10.1016/j.vaccine.2013.10.029.

PMID:
24144478
16.

Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.

Bengtsson KL, Song H, Stertman L, Liu Y, Flyer DC, Massare MJ, Xu RH, Zhou B, Lu H, Kwilas SA, Hahn TJ, Kpamegan E, Hooper J, Carrion R Jr, Glenn G, Smith G.

Vaccine. 2016 Apr 7;34(16):1927-35. doi: 10.1016/j.vaccine.2016.02.033.

17.

Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine.

Papaneri AB, Bernbaum JG, Blaney JE, Jahrling PB, Schnell MJ, Johnson RF.

Virus Res. 2015 Feb 2;197:54-8. doi: 10.1016/j.virusres.2014.11.028.

18.

Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus.

Wong G, Qiu X.

Methods Mol Biol. 2016;1403:245-57. doi: 10.1007/978-1-4939-3387-7_12.

PMID:
27076134
19.

Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals.

Wong G, Richardson JS, Cutts T, Qiu X, Kobinger GP.

Antiviral Res. 2015 Apr;116:17-9. doi: 10.1016/j.antiviral.2015.01.001.

20.

Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.

Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H.

J Infect Dis. 2011 Nov;204 Suppl 3:S1066-74. doi: 10.1093/infdis/jir348.

Items per page

Supplemental Content

Support Center